Media Thread, page-851

I just had a re-read of the latest PD1-Vaxx announcement. Below is an excerpt:

After 6 weeks (day 43) treatment with PD1-Vaxx, one patient’s tumor was non-measurable indicating a complete response (CR), with three patients showing stabilization of disease (SD) and a single patient progressing (PD). The status of two patients from cohort 1 (1 x SD, 1 x CR) were unchanged 2 IMUGENE LIMITED ACN 009 179 551 at day 85. These are encouraging results in patients who have progressed after previous treatment with checkpoint inhibitors including Keytruda®, Opdivo® or Tecentriq®. Further results and scans are scheduled over the coming weeks.

I actually missed the bold italic bit as I was busy when the announcement was released so had skim read it. I did not realise the patients had no success with the likes of Keytruda, Opdivo and Tecentriq! If the results is confirmed over the scheduled scans and replicated in Phase II, I dare say the likes of BeiGene might actually come knocking! That is if they truly want to knock Keytruda and Opdivo off their perch.